Everstar Asset Management’s Moderna MRNA Stock Holding History

Everstar Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,136	Closed	-$410K	–	197
2024 Q3	$410K	Buy	+6,136	New	+$563K	0.28%	106

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Everstar Asset Management's MRNA Position: Q4 2024 in Review

Everstar Asset Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 6,136 shares — an estimated $410K sold.

Everstar Asset Management first reported a position in MRNA in Q3 2024 and held it in 1 quarter. The position peaked at $410K in Q3 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

Everstar Asset Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
Everstar Asset Management sold 6,136 Moderna shares in Q4 2024, an estimated $410K.
Everstar Asset Management first reported a position in Moderna in Q3 2024 and held it in 1 quarter.
Everstar Asset Management's Moderna position peaked at $410K in Q3 2024.
745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Everstar Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.